<DOC>
	<DOCNO>NCT00073255</DOCNO>
	<brief_summary>To assess tolerability safety hOKT3g1 ( Ala-Ala ) 12-day dose regimen administer via intravenous infusion . To assess pharmacokinetics hOKT3g1 ( Ala-Ala ) .</brief_summary>
	<brief_title>Safety Pharmacokinetics ( PK ) hOKT3g1 ( Ala-Ala ) Type 1 Diabetes Mellitus ( T1DM )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>To eligible participant Type 1 diabetes , diagnose within previous 12 month establish standard American Diabetes Association criterion . All participant autoantibody : either antiGAD65 , antiICA512 , treat insulin le 7 day , antiinsulin . The age range 8 30 year ; minimum weight 34 kg .</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>